Beijing Med-Pharm to Market Ferriprox(R) in China.

Signs Five Year Exclusive Agreement with Canada's Largest Pharmaceutical Company

PLYMOUTH MEETING, Pa. -- Beijing Med-Pharm Corporation (NASDAQ:BJGP) ("Beijing Med-Pharm" or the "Company"), today announced that it has signed an exclusive, renewable five year agreement with Apotex Inc., to market and distribute Ferriprox[R] (Deferiprone) in the People's Republic of China.

Ferriprox[R] treats iron overload in the bloodstream which is often associated with thalassemia, a disease that can lead to organ damage and heart failure. Thalassemia is particularly prevalent in humid environments, like in Southern China, where it is estimated that 7-8% of the population needs treatment for the disease. Ferriprox[R] is currently sold in over 50 countries worldwide and is already approved for sale by China's State Food & Drug Administration ("SFDA"). Ferriprox is the only oral formulation in the class of iron chelator in China, and has proven to be very effective in reducing chronic iron overload, especially in the heart.

"Today's announcement exemplifies our efforts to partner with world-class pharmaceutical companies seeking a stronger, more effective presence in China. We are very pleased to add Ferriprox[R] to our growing portfolio of products. With SFDA approval already achieved for Ferriprox[R], we can directly focus on enhancing marketing and distribution results," stated David Gao, Chief Executive Officer of Beijing Med-Pharm.

Through the agreement, Beijing Med-Pharm will work closely with ApoPharma Inc., which is a subsidiary of Apotex Inc. devoted to the discovery and development of new medications to treat disorders of iron metabolism and also selected diseases of the skin.

Dr. Michael Spino, President of ApoPharma Inc., stated "We are delighted to formalize this partnership with Beijing Med-Pharm, a company which has already demonstrated its competency in effectively selling, marketing and distributing leading medications in China. There is a need to provide a cost-effective oral iron chelator to thalassemia patients in China to improve and prolong life. We believe that Beijing Med-Pharm's proven capabilities can be harnessed to educate thalassemia care givers and ensure that Ferriprox[R] is readily available throughout the region."

About Apotex Inc.

Apotex Inc. is the largest Canadian-owned pharmaceutical company, headquartered in Ontario with 5,500 employees and 21 facilities. It exports medicines to 115 countries and has an R&D budget expenditure planned of $2.0 billion over the next 10 years. Apotex researches, develops and manufactures over 300 medicines and fills over 72 million prescriptions in Canada per year.

About ApoPharma Inc.

ApoPharma Inc. is a Canadian pharmaceutical company that is devoted to the discovery and development of new medications to treat disorders of iron metabolism and also selected diseases of the skin. ApoPharma is a subsidiary of Apotex Inc., which is one of the most successful generic pharmaceutical companies in the world. Ferriprox has been approved in 54 countries for the treatment of iron overload in thalassemia and was the first oral iron chelator to be approved in Europe.

About Beijing Med-Pharm Corporation

Beijing Med-Pharm Corporation, through its subsidiaries, is a pharmaceutical marketing and distribution company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China and is pursuing partnerships with other companies seeking to enter the Chinese pharmaceutical market. It is the only U.S. public company to offer industry partners a comprehensive suite of market-entry services in China that includes pre-market entry analysis, clinical trial management, product registration, market research, as well as pharmaceutical marketing and distribution. The company provides distribution services for a wide range of products, including Western medicines, traditional Chinese medicines, bio-chemical medicines, medical applications, branded generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies and equipments. Beijing Med-Pharm's proprietary portfolio, primarily focusing on women's health and pediatrics, comprises Propess, Misopess, Anpo and Fentora. The Company is headquartered in Plymouth Meeting, Pennsylvania. Visit www.beijingmedpharm.com.